

April 9, 2020

Listing Department
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai – 400001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400051

Code: CADILAHC

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a Press Release dated April 7, 2020 titled “Zydus receives final approval from USFDA for Imatinib Mesylate Tablets”.

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors’ at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus receives final approval from USFDA for Imatinib Mesylate Tablets

Ahmedabad, April 9, 2020

Zydus Cadila has received final approval from the USFDA to market Imatinib Mesylate Tablets, 100 mg and 400 mg. (US RLD: Gleevec® Tablets)

This medication is used to treat certain types of leukemia (blood cancer), bone marrow disorders, skin cancer and tumors of the stomach and digestive system. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, in Ahmedabad.

The group now has 285 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
